BR112012017054A2 - "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" - Google Patents
"análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"Info
- Publication number
- BR112012017054A2 BR112012017054A2 BR112012017054A BR112012017054A BR112012017054A2 BR 112012017054 A2 BR112012017054 A2 BR 112012017054A2 BR 112012017054 A BR112012017054 A BR 112012017054A BR 112012017054 A BR112012017054 A BR 112012017054A BR 112012017054 A2 BR112012017054 A2 BR 112012017054A2
- Authority
- BR
- Brazil
- Prior art keywords
- well
- pharmaceutical composition
- peptide analog
- oxintomodulin peptide
- oxintomodulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
patente de invenção: "análogo de peptídeo de oxintomodulina" a presente invenção refere-se a análogos de peptídeo de oxitomodulina úteis no tratamento de diabetes e/ou obsidade.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28888409P | 2009-12-22 | 2009-12-22 | |
US35256910P | 2010-06-08 | 2010-06-08 | |
PCT/US2010/060380 WO2011087671A1 (en) | 2009-12-22 | 2010-12-15 | Oxyntomodulin peptide analogue |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012017054A2 true BR112012017054A2 (pt) | 2016-11-22 |
Family
ID=43568014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012017054A BR112012017054A2 (pt) | 2009-12-22 | 2010-12-15 | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" |
Country Status (27)
Country | Link |
---|---|
US (1) | US8415296B2 (pt) |
EP (1) | EP2515927B1 (pt) |
JP (1) | JP5717758B2 (pt) |
KR (1) | KR101399692B1 (pt) |
CN (1) | CN102665752B (pt) |
AR (1) | AR079344A1 (pt) |
AU (1) | AU2010341650B2 (pt) |
BR (1) | BR112012017054A2 (pt) |
CA (1) | CA2784668C (pt) |
CL (1) | CL2012001685A1 (pt) |
CO (1) | CO6551737A2 (pt) |
CR (1) | CR20120339A (pt) |
DO (1) | DOP2012000175A (pt) |
EA (1) | EA201290557A1 (pt) |
EC (1) | ECSP12011988A (pt) |
ES (1) | ES2512141T3 (pt) |
GT (1) | GT201200205A (pt) |
HK (1) | HK1170943A1 (pt) |
MA (1) | MA33826B1 (pt) |
MX (1) | MX2012007449A (pt) |
NZ (1) | NZ600732A (pt) |
PE (1) | PE20121721A1 (pt) |
SG (1) | SG181872A1 (pt) |
TN (1) | TN2012000303A1 (pt) |
TW (1) | TWI451873B (pt) |
UA (1) | UA106399C2 (pt) |
WO (1) | WO2011087671A1 (pt) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
ES2507098T3 (es) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
EP2487184A1 (en) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
ES2402172T3 (es) | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
AU2008318986B2 (en) | 2007-10-30 | 2014-12-04 | Indiana University Research And Technology Corporation | Glucagon antagonists |
CA2702289A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
PE20100056A1 (es) | 2008-06-17 | 2010-01-26 | Univ Indiana Res & Tech Corp | Analogos de glucagon como agonistas gip |
CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
JO2976B1 (en) * | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
JP2013518115A (ja) | 2010-01-27 | 2013-05-20 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物 |
CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
BR112012028704A2 (pt) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | composto de glugagon da superfamília de peptídeos exibindo atividade do receptor com hormônio nuclear, pró fármaco, dímero ou multímero, composição farmacêutica que o compreendem e método de administração do mesmo. |
CN103458920B (zh) | 2010-12-22 | 2016-07-06 | 印第安那大学科技研究公司 | 表现出gip受体活性的胰高血糖素类似物 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
EP2714070B1 (en) * | 2011-06-02 | 2024-03-20 | OPKO Biologics Ltd. | Long-acting glp-1/glucagon receptor agonists |
SG10201604564XA (en) | 2011-06-10 | 2016-07-28 | Hanmi Science Co Ltd | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
UA114709C2 (uk) | 2011-06-17 | 2017-07-25 | Ханмі Сайенс Ко., Лтд. | Кон'югат, що містить похідну оксинтомодуліну, fc-ділянку імуноглобуліну та непептидильний полімер, та його застосування |
RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
KR20140043793A (ko) | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
JP2015520128A (ja) * | 2012-04-19 | 2015-07-16 | オプコ バイオロジクス リミテッド | 長時間作用性オキシントモジュリン変異体とその作製方法 |
AU2013273135B2 (en) | 2012-06-04 | 2017-12-07 | Opko Biologics Ltd. | Pegylated OXM variants |
KR20150023013A (ko) | 2012-06-21 | 2015-03-04 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 수용체 활성을 나타내는 글루카곤 유사체 |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
NZ739063A (en) | 2012-11-06 | 2019-11-29 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
UA116553C2 (uk) | 2012-12-21 | 2018-04-10 | Санофі | Пептидна сполука - агоніст рецептора glp-1 i glp |
KR20150132362A (ko) * | 2013-03-15 | 2015-11-25 | 에이다에레이타, 리미티드 파트너쉽 | Pcsk9의 소분자 조절물질 및 그것의 사용 방법 |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
KR20240037175A (ko) | 2016-05-16 | 2024-03-21 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
IL307966A (en) | 2017-01-03 | 2023-12-01 | Intarcia Therapeutics Inc | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
CN108299554B (zh) * | 2017-01-13 | 2021-05-25 | 博瑞生物医药(苏州)股份有限公司 | 胃泌酸调节素类似物 |
CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素(oxm)类似物及其应用 |
US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5445090A (en) | 1991-07-25 | 1995-08-29 | Mim Industries, Inc. | Interchangeable clamp for use in a sewing machine |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
EP1061954B1 (en) | 1998-03-12 | 2004-06-09 | Nektar Therapeutics Al, Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
CA2394980C (en) | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
UA92451C2 (en) | 2003-03-19 | 2010-11-10 | Эли Лилли Энд Компани | Polyethelene glycol link glp-1 compounds |
EA012442B1 (ru) | 2005-05-13 | 2009-10-30 | Эли Лилли Энд Компани | Пегилированные соединения glp-1 |
PL1891105T3 (pl) | 2005-06-13 | 2012-09-28 | Imperial Innovations Ltd | Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe |
ES2507098T3 (es) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
JP5297817B2 (ja) * | 2006-02-22 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | オキシントモジュリン誘導体 |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
EP2487184A1 (en) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
JP5606314B2 (ja) | 2007-09-05 | 2014-10-15 | ノボ・ノルデイスク・エー/エス | A−b−c−d−で誘導体化されたペプチドとその治療用途 |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
-
2010
- 2010-12-09 AR ARP100104554A patent/AR079344A1/es unknown
- 2010-12-10 TW TW099143355A patent/TWI451873B/zh not_active IP Right Cessation
- 2010-12-15 JP JP2012546033A patent/JP5717758B2/ja active Active
- 2010-12-15 BR BR112012017054A patent/BR112012017054A2/pt not_active IP Right Cessation
- 2010-12-15 EP EP10799178.8A patent/EP2515927B1/en active Active
- 2010-12-15 WO PCT/US2010/060380 patent/WO2011087671A1/en active Application Filing
- 2010-12-15 NZ NZ600732A patent/NZ600732A/en not_active IP Right Cessation
- 2010-12-15 ES ES10799178.8T patent/ES2512141T3/es active Active
- 2010-12-15 CA CA2784668A patent/CA2784668C/en active Active
- 2010-12-15 US US12/968,388 patent/US8415296B2/en active Active
- 2010-12-15 PE PE2012000855A patent/PE20121721A1/es not_active Application Discontinuation
- 2010-12-15 MX MX2012007449A patent/MX2012007449A/es active IP Right Grant
- 2010-12-15 AU AU2010341650A patent/AU2010341650B2/en not_active Ceased
- 2010-12-15 EA EA201290557A patent/EA201290557A1/ru unknown
- 2010-12-15 SG SG2012046223A patent/SG181872A1/en unknown
- 2010-12-15 CN CN201080058422.4A patent/CN102665752B/zh active Active
- 2010-12-15 KR KR1020127016092A patent/KR101399692B1/ko active IP Right Grant
- 2010-12-15 UA UAA201207074A patent/UA106399C2/ru unknown
-
2012
- 2012-06-14 MA MA34969A patent/MA33826B1/fr unknown
- 2012-06-14 TN TNP2012000303A patent/TN2012000303A1/en unknown
- 2012-06-20 DO DO2012000175A patent/DOP2012000175A/es unknown
- 2012-06-20 GT GT201200205A patent/GT201200205A/es unknown
- 2012-06-20 EC ECSP12011988 patent/ECSP12011988A/es unknown
- 2012-06-21 CO CO12104387A patent/CO6551737A2/es active IP Right Grant
- 2012-06-21 CL CL2012001685A patent/CL2012001685A1/es unknown
- 2012-06-22 CR CR20120339A patent/CR20120339A/es not_active Application Discontinuation
- 2012-11-19 HK HK12111774.5A patent/HK1170943A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012017054A2 (pt) | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" | |
BR112012017348A2 (pt) | "análogo de peptídeo de oxintomodulina" | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
SV2011004019A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
CL2008001125A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
BR112015013809A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica | |
CL2008001126A1 (es) | Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad. | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
CO6280490A2 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
CL2008001994A1 (es) | Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras. | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
IL210364A (en) | Beta-amyloid peptide cyclic peptide analogue and its use in the treatment and diagnosis of neurodegenerative diseases or conditions | |
ECSP088745A (es) | Derivados sustituidos de cromanol y su uso | |
CL2008003546A1 (es) | Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii. | |
ECSP11011101A (es) | Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento | |
PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso | |
CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
WO2010052243A3 (en) | Neurotensin-derived branched peptides and uses thereof | |
CL2012000355A1 (es) | Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc. | |
UA44395U (ru) | Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении | |
CL2014001815A1 (es) | Compuesto inhibidor ciclico de 11beta-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica; y el uso del mismo en enfermedades tales como diabetes (div. sol. 2697-11). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |